2017 Section 7 Green Book

201 / 220

OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here:
OncoTargets and Therapy is an international, peer-reviewed, open
access journal focusing on the pathological basis of all cancers, potential
targets for therapy and treatment protocols employed to improve the
management of cancer patients. The journal also focuses on the impact
of management programs and new therapeutic agents and protocols on
patient perspectives such as quality of life, adherence and satisfaction.
The manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use. Visit
to read real quotes from
published authors.
OncoTargets and Therapy 2016:9 submit your manuscript |
Efficacy and safety of VEGFR-TKIs in ATC
15. Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in
patients with cancer treated with cisplatin: a systematic review and
meta-analysis. J Clin Oncol . 2012;30(35):4416–4426.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring incon-
sistency in meta-analyses. BMJ. 2003;327(7414):557–560.
17. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of
genome searches. Genet Epidemiol. 2005;28(2):123–137.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited.
Contemp Clin Trials. 2015;45:139–145.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
20. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: random-
ized, open-label, phase III study of first-line pemetrexed + carboplatin
followed by maintenance pemetrexed versus paclitaxel + carboplatin +
bevacizumab followed by maintenance bevacizumab in patients ith
advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol.
2015;10(1):134–142.
21. Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind,
placebo-controlled, multicenter, phase III study of first-line carboplatin/
paclitaxel plus bevacizumab or placebo in Chinese patients with
advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin
Oncol. 2015;33(19):2197–2204.
22. Galetta D, Cinieri S, Pisconti S, et al. Cisplatin/pemetrexed followed by
maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab
followed by maintenance bevacizumab in advanced nonsquamous
lung cancer: The GOIM (Gruppo Oncologico Italia Meridionale)
ERACLE phase III randomized trial. Clin Lung Cancer. 2015;16(4):
262–273.
23. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab
as first-line therapy in patients with advanced non-squamous non-
small-cell lung cancer harbouring EGFR mutations (JO25567): an
open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;
15(11):1236–1244.
24. Niho S, Kunitoh H, Nokihara H, et al. Randomized phase II study
of first-line carboplatin-paclitaxel with or without bevacizumab in
Japanese patients with advanced non-squamous non-small-cell lung
cancer. Lung Cancer. 2012;76(3):362–367.
25. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus
erlotinib versus erlotinib alone in advanced non-small-cell lung cancer
after failure of standard first-line chemotherapy (BeTa): a double-blind,
placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846–1854.
26. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus
gemcitabine with either placebo or bevacizumab as first-line therapy for
nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;
27(8):1227–1234.
27. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;
355(24):2542–2550.
28. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized
phase II trial comparing bevacizumab plus carboplatin and paclitaxel
with carboplatin and paclitaxel alone in previously untreated locally
advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;
22(11):2184–2191.
29. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive
medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646.
30. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with
locally advanced or metastatic medullary thyroid cancer: a randomized,
double-blind phase III trial. J Clin Oncol . 2012;30(2):134–141.
31. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive
iodine-refractory, locally advanced or metastatic differentiated thy-
roid cancer: a randomised, double-blind, phase 3 trial. Lancet . 2014;
384(9940):319–328.
32. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally
advanced or metastatic differentiated thyroid cancer: a randomised,
double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897–905.
33. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus pla-
cebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;
372(7):621–630.
34. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl
J Med. 1971;285(21):1182–1186.
35. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors.
Ann Surg. 1972;175(3):409–416.
36. Lin JD, Chao TC. Vascular endothelial growth factor in thyroid cancers.
Cancer Biother Radiopharm. 2005;20(6):648–661.
37. Weitzman SP, Cabanillas ME. The treatment landscape in thyroid can-
cer: a focus on cabozantinib. Cancer Manag Res. 2015;7:265–278.
38. Yeung KT, Cohen EE. Lenvatinib in advanced, radioactive iodine-
refractory, differentiated thyroid carcinoma. Clin Cancer Res. 2015;
21(24):5420–5426.
39. Ferrari SM, Politti U, Spisni R, et al. Sorafenib in the treatment of
thyroid cancer. Expert Rev Anticancer Ther. 2015;15(8):863–874.
40. Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with
vandetanib in cancer patients: a systematic review and meta-analysis
of clinical trials. Br J Clin Pharmacol. 2013;75(4):919–930.
41. Qi WX, Lin F, Sun YJ, et al. Incidence and risk of hypertension with
pazopanib in patients with cancer: a meta-analysis. Cancer Chemother
Pharmacol. 2013;71(2):431–439.
42. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hyper-
tension with sorafenib in patients with cancer: a systematic review and
meta-analysis. Lancet Oncol. 2008;9(2):117–123.
43. Zhang ZF, Wang T, Liu LH, Guo HQ. Risks of proteinuria associated
with vascular endothelial growth factor receptor tyrosine kinase inhibi-
tors in cancer patients: a systematic review and meta-analysis. PLoS
One. 2014;9(3):e90135.
44. Sonpavde G, Je Y, Schutz F, et al. Venous thromboembolic events with
vascular endothelial growth factor receptor tyrosine kinase inhibitors:
a systematic review and meta-analysis of randomized clinical trials.
Crit Rev Oncol Hematol. 2013;87(1):80–89.
45. Qi WX, Min DL, Shen Z, et al. Risk of venous thromboembolic events
associated with VEGFR-TKIs: A systematic review and meta-analysis.
Int J Cancer. 2013;132(12):2967–2974.
46. Qi WX, Tang LN, Sun YJ, et al. Incidence and risk of hemorrhagic
events with vascular endothelial growth factor receptor tyrosine-kinase
inhibitors: an up-to-date meta-analysis of 27 randomized controlled
trials. Ann Oncol . 2013;24(12):2943–2952.
47. Hong S, Fang W, Liang W, et al. Risk of treatment-related deaths with
vascular endothelial growth factor receptor tyrosine kinase inhibitors:
a meta-analysis of 41 randomized controlled trials. Onco Targets Ther.
2014;7:1851–1867.
PoweredbyTCPDF )
181